Article

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

Department of Urology, Medical University of Lübeck, Lübeck, Germany.
The Journal of Urology (Impact Factor: 3.75). 01/2003; 169(1):90-5. DOI: 10.1097/01.ju.0000039680.90768.b3
Source: PubMed

ABSTRACT We compare the therapeutic efficacy and toxicity of intravesical bacillus Calmette-Guerin (BCG) with mitomycin C on recurrence of stages Ta and T1 bladder carcinoma.
Combined published and unpublished data from comparative studies on BCG versus mitomycin C for superficial bladder carcinoma considering possible confounding factors were analyzed. Odds ratio (OR) and its 95% CI were used as primary effect size estimate. Toxicity data were evaluated descriptively.
In 11 eligible clinical trials 1,421 patients were treated with BCG and 1,328 were treated with mitomycin C. Within the overall median followup time of 26 months 38.6% of the patients in the BCG group and 46.4% of those in the mitomycin C group had tumor recurrence. In 7 of 11 studies BCG was significantly superior to mitomycin C, in 3 studies no significant difference was found, while in 1 study mitomycin C was significantly superior to BCG. An overall statistically significant superiority of BCG versus mitomycin C efficacy in reducing tumor recurrence was detected (OR 0.56, 95% CI 0.38 to 0.84, p = 0.005). In the subgroup treated with BCG maintenance all 6 individual studies showed a significant superiority of BCG over mitomycin C (OR 0.43, 95% CI 0.35 to 0.53, p <0.001). In 4 of the 5 studies with reported data on toxicity BCG associated cystitis was significantly more frequent than in the mitomycin C group (53.8% versus 39.2%). The combined cystitis OR was 1.81 (95% CI 1.48 to 2.23, p <0.001). The OR for cystitis in the BCG maintenance group did not significantly differ from that in the nonmaintenance therapy group.
The results suggest superiority of BCG over mitomycin C for prevention of tumor recurrences in the combined data and particularly in the BCG maintenance treatment subgroup, irrespective of the actual (intermediate or high) tumor risk status. The toxicity with BCG is higher but does not differ between BCG maintenance and nonmaintenance groups.

0 Bookmarks
 · 
60 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 3 DERLEME M esane kanseri üriner sistemin en sık görülen kanseridir. Mesane kanserlerinin %90-95'ini ürotelyal karsinom-lar oluşturur (1). Ürotelyal karsinomların %75-85'i tanı anında kasa invaze olmayan mesane kanseri (KİOMK) şeklinde olup, %70'i Ta, %20'si T1 ve %10'u karsinoma in situ (CIS) ev-resindedir (2,3). KİOMK'un doğal gidişi tam olarak bilinmemektedir. KİOMK'nin en önemli özelliği nüks ve progresyon açısından hetero-jen biyolojik davranış göstermesidir. Spektrumun bir ucunda düşük nüks ve progresyon gösteren düşük malignite potansiyelli papiller ürotelyal neoplazm (papillary urothelial neoplasm of low malignant potential-PUNLMP) ve Ta düşük dereceli papiller ürotelyal karsinom (low grade papillary urothelial carcinoma-TaLG) varken diğer ucunda T1 yüksek dereceli papiller ürotelyal karsinom (high grade papillary urothelial carcinoma-TaHG) ve CIS yer alır (3-6,7-45). Yüksek riskli tümörleri belirlemek ne kadar önemli ise düşük riskli tümörleri de belirlemek o kadar önemlidir, çünkü bu hastaları gereksiz takip ve tedavi işlemlerinden korumak gereklidir. 1998'de oluşturulan WHO/ ISUP (Dünya Sağlık Örgütü/Uluslararası Ürolojik Patoloji Derneği) sınıflaması bu amaca hizmet etmektedir. WHO 1973 tümör derecesi sınıflaması ile prognozu daha iyi gösterdiği ileri sürülen WHO/ISUP sınıflaması karşılaştırıldığında derece 1 tümörlerin PUNLMP ve düşük dereceli papiller ürotelyal karsinom, derece 2 tümörlerin düşük dere-celi papiller ürotelyal karsinom ve yüksek dereceli papiller ürotelyal karsinom, ve derece 3'ün de yüksek dereceli papiller ürotelyal kar-sinoma karşılık geldiği görülmektedir (4). WHO/ISUP sınıflamasının ABSTRACT Non-muscle invasive bladder cancer includes a group of uro-thelial cancers having heterogeneous characteristics. As a rule, they show recurrence and progression. The principle of surveil-lance and management of these tumors is decreasing recurrence rate and preventing progression. Based on this principle, sur-veillance policy is created according to clinical and pathological characteristics of tumors. While appropriate management is go-ing on, over-followup in low risk group and less frequent followup in high risk group should not be done. Cystoscopy and urinary cytology are worldwide accepted diagnostic tools. Recently, since psychological effect and high economic burden on patients, the approach of reducing frequency and duration of followup cystos-copies in patients with low risk has been popularized in devel-oping followup schedules. In this text, the fundamentals of this approach is reviewed. ÖZET Kasa invaze olmayan mesane tümörü heterojen özellikler içeren bir ürotelyal kanserdir. En önemli özellikleri nüks ve progresyon göstermeleridir. Bu tümörlerin takip ve tedavisindeki temel amaç-lar nüksü azaltmak ve progresyonu önlemektir. Bu amaca yönelik takip programları, tümörün klinik ve patolojik özellikleri dikkate alınarak oluşturulan risk gruplarına göre yapılır. Yeterli tedavi ve-rirken, düşük risk grubuna aşırı takip, yüksek risk grubuna yetersiz takip uygulamamak gerekir. Sistoskopi ve idrar sitolojisi takipte kabul görmüş yöntemlerdir. Son zamanlarda, yüksek maliyet ve hasta üzerindeki psikolojik etkisi nedeniyle, sistoskopi aralıklarını düşük risk grubu hastalarda uzatma yönünde görüşler hasta takip programlarına hakim olmaya başlamıştır. Bu derlemede bu görüş-lerin temel noktaları incelenmektedir.
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bladder cancer is the second most common urological cancer in the UK, with over 10 000 cases diagnosed annually. With 80% of urothelial bladder cancers being non-muscle invasive, it is important to understand the treatments available. This review aims to identify and review the literature regarding bacillus Calmette-Guerin (BCG) treatment. An integrative-based review was conducted to generate a broad overview of the existing knowledge for BCG treatment. An open search of online databases was conducted to identify articles published in English from the earliest date available to September 2013, using key terms related to BCG. A significant number of articles were identified. To narrow the results and identify the most relevant articles, the search terms were cross-referenced. The resulting articles were then reviewed using the critical appraisal skills programme framework. The tools provided by CASP give a systematic, transparent and rigorous approach to the quality assessment of research studies. The research articles were then categorized under the following headings: side effects, including local, systemic and age; quality of life; and attrition. The major conclusion from this literature review is that BCG treatment, when given through an induction and maintenance regime, significantly reduces the risk of progression and recurrence. However, there are potential side effects which the patient and the nurse need to be aware. This review also highlighted that there is a lack of research from the UK and that there is a paucity of research showing why patients withdraw from BCG treatment
    International Journal of Urological Nursing 10/2014; · 0.19 Impact Factor